

EQA round: KD2/25 - Glycated Haemoglobin

Deadline: 4.4.2025

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average

AV = assigned value

D_{max} = acceptable difference

SD = standard deviation

CVP = consensus of all participants

LL = lower limit

CV = coefficient of variation

U_{AV} = expanded uncertainty of the assigned value (k = 2)

UL = upper limit

N_{tot} = total number of the resultsN_{eva} = number of the results assessedN_{out} = number of the results removed before calculationN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability									
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel} [%]		
(220) Haemoglobin A_{1c}	[mmol/mol]				153							153	148	97		
Sample A		52,9	1,9	3,7	153		CVP	52,9	0,39	asym.	47	59	153	148	97	
(14) Bio-Rad		52,8	1,7	3,2	43	1							43			
(25) TOSOH		54,5	1,7	3,1	34	0							34			
(34) Sebia		52,8	0,77	1,5	10	0							10			
(60) Roche		52,3	2,6	5	13	0							13			
(150) Arkray		52,4	1,6	3,1	43	1							43			
Other					10	0							10			
								2x 1, 3x 46, 2x 58, 1x 162, 1x 177, 1x 999								
Sample B		40,7	1,6	3,9	153		CVP	40,7	0,32	asym.	36	45	153	150	98	
(14) Bio-Rad		40,1	1,4	3,6	43	1							43			
(25) TOSOH		41,2	1,5	3,7	34	0							34			
(34) Sebia		39,7	0,55	1,4	10	0							10			
(60) Roche		40,3	2,1	5,1	13	0							13			
(150) Arkray		41,3	1,3	3,2	43	0							43			
Other					10	0							10			
								2x 1, 3x 46, 2x 58, 1x 162, 1x 177, 1x 999								